Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.
Volume: 38, Issue: 15_suppl, Pages: 4585 - 4585
Published: May 20, 2020
Abstract
4585 Background: The IMbrave150 pivotal study in unresectable HCC showed superiority of atezolizumab + bevacizumab (atezo + bev) vs sorafenib for OS and PFS. Based on these data supporting first-line atezo + bev for HCC, we conducted a network meta-analysis (NMA) to compare the efficacy of atezo + bev with other systemic and local therapies approved for HCC. Methods: A systematic literature review identified randomized controlled trials in...
Paper Details
Title
Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.
Published Date
May 20, 2020
Journal
Volume
38
Issue
15_suppl
Pages
4585 - 4585
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History